Society of Nuclear Medicine and Molecular Imaging May 31 2026 A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options. This novel approach, presented at the Society of Nuclear Medicine 2026 Annual Meeting, resulted in partial remission of the disease in the majority of patients with advanced cases of neuroendocrine tumors. Neuroendocrine tumors are a type of cancer that begins